Clinical Trial Update: Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial evaluating pembrolizumab with HER2-targeted therapy for HER2-positive breast cancer, with results posted in May 2025 and the trial c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: HER2-positive Breast Cancer, Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-05-08